MindCure (MCUR.C) – First Glance with Jody Vance (Ep 75)

Jody speaks with the president & CEO of Mindcure (MCUR.C), Kelsey Ramsden, to get a better idea of how the company combines psychedelic research, technology, and medicines to optimize mental health care. Tune in!

The post MindCure (MCUR.C) – First Glance with Jody Vance (Ep 75) appeared first on Equity.Guru.

Post date
November 3, 2021
Posted by
Reza Golzadeh
Posted in 2021 psychedelic stocks, first gla, Health Science, mental health, mindcure, Psychedelics, Scribes, Series, Today's Analysis, Vance, Video, Wellness
Comments
0

Leave a Reply Cancel reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Why DARPA is reviving psychedelics research for the U.S. military in the shadow of MK-Ultra

Cambridge house, psychedelics, pharma, one up, mindmed

Cambridge House’s XFuture event spearheads brave new world of psychedelic treatments

PsyBio (PSYB.V) files provisional patent application for psilocybin and norbaeocystin composition and treatment

Post date
July 13, 2021
Posted by
Piers Eaton
Posted in baeocystin, Biotech, Eaton, Health Science, Mushrooms, Norbaeocystin, psilocybin, PSYB.V, PsyBio, PsyBio therapeutics, Psychedelics, Scribes
Comments
0

Canadian Psychedelic Stocks – To Invest or Not

Post date
November 24, 2021
Posted by
Reza Golzadeh
Posted in 2022 canadian psychedelics stocks, Golzadeh, invest or not, mindcure, Mushrooms, MYND Life Sciences, neonmind biosciences, Psychedelics, Today's Analysis, Video
Comments
0

%d bloggers like this: